Osteoporosis and Bone Disorders

Top Story

Romosozumab followed by denosumab decreases fracture risk in postmenopausal women

Romosozumab followed by denosumab decreases fracture risk in postmenopausal women
September 18, 2017

The risks for new vertebral, clinical and nonvertebral fractures were reduced and bone mineral density increased in postmenopausal women assigned romosozumab followed by denosumab, according to results from the FRAME extension study presented at the American Society for Bone and Mineral Research Annual Meeting.

In the original FRAME study, 7,180 postmenopausal women were assigned to receive subcutaneous placebo or romosozumab (Amgen/UCB Pharma) monthly for 12 months followed by open-label subcutaneous denosumab (Prolia, Amgen) every 6 months for 12 months.

Meeting News

HbA1c levels, diabetes duration linked to fracture risk

September 18, 2017
Adults with type 2 diabetes and obesity are at increased risk for any fracture, major osteoporotic fractures and hip fractures with longer duration of diabetes and…
In the Journals

Physical activity did not change 6 months after total hip or knee arthroplasty

September 15, 2017
There was no significant change in physical activity 6 months after total knee or hip joint replacement surgery, despite improvements in quality of life, pain and…
In the Journals

Burden of arthritis expected to increase among Australians

September 15, 2017
A population-level study for Australia, projected an increased prevalence of osteoarthritis and rheumatoid arthritis and health care costs related to these conditions…
More Headlines »
CME

Operative Management Options for Traumatic Anterior Shoulder Instability in Patients Younger Than 30 Years: September 2015

Anterior instability of the glenohumeral joint is a relatively common problem in the young population. Identification…
More »
Video
Meeting News

VIDEO: Osteoporosis is a silent disease

August 11, 2017
More »
Resource Centers
Rheumatology Nurses Society Annual Conference

Rheumatology Nurses Society Annual Conference

CME ABIM MOC

Ace the Case: A 29-year-old Woman with Psoriasis Vulgaris

There is no commercial support for this activity.

This “Ace the Case” study will discuss the assessment and treatment of a 29-year-old woman with Psoriasis Vulgaris…
More »
Advertisement
Advertisement